US · Healthcare · Biotechnology
EPS came in at 2.05 against a street estimate of 1.40 — a beat of 46.4%.
Analysts rate BeiGene, Ltd. a strong buy (23 buy, 1 hold, 0 sell out of 24) with an average price target of $432.16.
CONFIDENT BeOne posted 30% revenue growth to $1.7B, raised FY26 guidance by $300M on BRUKINSA momentum and favorable duration data. Pipeline inflection underway with BEQALZI approval, MANGROVE chemo-free MCL win, and 5 solid tumor programs advancing to pivotal stage. Q2 2026 U.S. driven by BRUKINSA strength and new patient starts. China maintained leadership in TEVIMBRA/BRUKINSA; FX added 7% reported growth (renminbi strength). Europe strongest growth driver at +37%. Rest of World doubled on Japan, Brazil momentum. Analysts pressed competitive dynamics (Acala, Pirto) and long-term durability; management emphasized 6-year BRUKINSA PFS (70% unmutated IGHV) vs. fixed-duration competitors (40s) and lack of comparable Pirto long-term data. CELESTIAL-301 uMRD miss deflected to PFS primary endpoint and historical VO data interpretation. Tacabrutideg and PRMT5/CEA near-term catalysts (Q4 AA, ESM…
Full summary in the app.
| Fund | Stake |
|---|---|
| Baker Bros Advisors LP | 7.78% |
| PRIMECAP Management Company | 4.43% |
| Capital Research & Mgmt Co - Division 3 | 3.72% |
| FMR Inc | 3.27% |
| Capital World Investors | 1.99% |
| Citadel Advisors Llc | 0.91% |
| Temasek Holdings Ltd. | 0.75% |
| BlackRock Inc | 0.58% |
| Document | Date |
|---|---|
| Results announced · Q3 2026 BEONE MEDICINES LTD. - INTERIM REPORT SUMMARY (H1 2026) HEADLINE NUMBERS • Total R&D expenses for six months ended June 30, 2026: $1,153.5 million ( | 2026-08-26 |
| Quarterly report · Q2 2026 BEONE MEDICINES LTD. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues (six months ended June 30, 2026): $3,218.5 million, up 32.4% vs. $2,43 | 2026-08-05 |
| Results announced · Q3 2026 BEONE MEDICINES Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total global revenues: $1.7 billion for Q2 2026, up 30% year-over-year • Product revenue | 2026-08-05 |
| Company announcement · Q2 2026 BEONE MEDICINES LTD. - DOCUMENT SUMMARY HEADLINE NUMBERS • Company concluded a statutory tax audit in China with settlement requiring income tax pay | 2026-06-26 |
| Board / officer change · Q2 2026 BEONE MEDICINES LTD. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 11, 2026 with 1,061,026,909 ordinary shares represented (73.36% of 1, | 2026-06-11 |
| Quarterly report · Q1 2026 BEONE MEDICINES LTD. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues Q1 2026: $1,513.4 million vs. $1,117.3 million Q1 2025 (+35.4%) • Prod | 2026-05-06 |
| Proxy statement · Q2 2026 BEONE MEDICINES LTD. — PROXY STATEMENT SUMMARY --- CEO COMPENSATION & CHANGE • John V. Oyler (Co-Founder, Chairman and CEO) total compensation figu | 2026-04-28 |
| Annual report FY2025 BEONE MEDICINES LTD. – 2025 FORM 10-K SUMMARY HEADLINE NUMBERS • Total global revenue: $5.3 billion in 2025, up 40.2% year-over-year • Net income: $ | 2026-02-26 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BeiGene, Ltd. — free to start.
Google PlayApp StoreData updated 2026-09-18.